Zentalis Pharmaceuticals, Inc. (ZNTL)
1.47
+0.11
(+8.09%)
USD |
NASDAQ |
Nov 20, 10:46
Zentalis Pharmaceuticals Cash from Operations (Quarterly) : -32.71M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -32.71M |
| June 30, 2026 | -37.24M |
| March 31, 2026 | -32.96M |
| December 31, 2025 | -30.94M |
| September 30, 2025 | -26.96M |
| June 30, 2025 | -34.71M |
| March 31, 2025 | -32.64M |
| December 31, 2024 | -39.70M |
| September 30, 2024 | -44.04M |
| June 30, 2024 | -35.14M |
| March 31, 2024 | -51.97M |
| December 31, 2023 | -40.60M |
| September 30, 2023 | -38.66M |
| June 30, 2023 | -79.28M |
| March 31, 2023 | -49.28M |
| December 31, 2022 | -37.33M |
| Date | Value |
|---|---|
| September 30, 2022 | -33.20M |
| June 30, 2022 | -43.03M |
| March 31, 2022 | -50.20M |
| December 31, 2021 | -37.02M |
| September 30, 2021 | -33.49M |
| June 30, 2021 | -46.11M |
| March 31, 2021 | -37.47M |
| December 31, 2020 | -27.36M |
| September 30, 2020 | -20.56M |
| June 30, 2020 | -22.03M |
| March 31, 2020 | -16.87M |
| December 31, 2019 | -13.19M |
| September 30, 2019 | -9.988M |
| June 30, 2019 | -6.958M |
| March 31, 2019 | -9.006M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | -33.71M |
| ACADIA Pharmaceuticals, Inc. | 11.50M |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
| Anika Therapeutics, Inc. | 8.377M |
| Savara, Inc. | -42.46M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -55.31M |
| Cash from Financing (Quarterly) | 87.26M |
| Free Cash Flow | -133.87M |
| Free Cash Flow Per Share (Quarterly) | -0.3866 |
| Free Cash Flow to Equity (Quarterly) | -31.72M |
| Free Cash Flow to Firm (Quarterly) | -32.71M |
| Free Cash Flow Yield | -92.68% |